MX9604367A - Hidroxipiridinonas novedosas. - Google Patents

Hidroxipiridinonas novedosas.

Info

Publication number
MX9604367A
MX9604367A MX9604367A MX9604367A MX9604367A MX 9604367 A MX9604367 A MX 9604367A MX 9604367 A MX9604367 A MX 9604367A MX 9604367 A MX9604367 A MX 9604367A MX 9604367 A MX9604367 A MX 9604367A
Authority
MX
Mexico
Prior art keywords
hydroxypyridinones
novel
iron
hydroxypyridin
warm
Prior art date
Application number
MX9604367A
Other languages
English (en)
Inventor
Paul Zbinden
Original Assignee
Novartis Ag Tambien Denominada
Y O Novartis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag Tambien Denominada, Y O Novartis Inc filed Critical Novartis Ag Tambien Denominada
Publication of MX9604367A publication Critical patent/MX9604367A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)

Abstract

Se describe 3-hidroxipiridin-4-onas de la formula (I): en donde R1-R4, A, y B, son como se definen en la descripcion. Los compuestos tienen valiosas propiedades farmacéuticas y son especialmente efectivos como queladores de hierro. Se pueden utilizar para tratar un exceso de hierro en los cuerpos de animales de sangre caliente.
MX9604367A 1995-09-29 1996-09-26 Hidroxipiridinonas novedosas. MX9604367A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH275995 1995-09-29

Publications (1)

Publication Number Publication Date
MX9604367A true MX9604367A (es) 1997-10-31

Family

ID=4240981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9604367A MX9604367A (es) 1995-09-29 1996-09-26 Hidroxipiridinonas novedosas.

Country Status (22)

Country Link
US (1) US5688815A (es)
EP (1) EP0768302B1 (es)
JP (1) JPH09124603A (es)
KR (1) KR970015576A (es)
CN (1) CN1151399A (es)
AR (1) AR005419A1 (es)
AT (1) ATE299135T1 (es)
AU (1) AU6584596A (es)
BR (1) BR9603929A (es)
CA (1) CA2186716A1 (es)
CZ (1) CZ284896A3 (es)
DE (1) DE59611243D1 (es)
ES (1) ES2244967T3 (es)
HU (1) HUP9602681A1 (es)
IL (1) IL119316A (es)
MX (1) MX9604367A (es)
NO (1) NO964095L (es)
NZ (1) NZ299452A (es)
PT (1) PT768302E (es)
SA (1) SA96170399B1 (es)
TR (1) TR199600765A2 (es)
ZA (1) ZA968150B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6448273B1 (en) 1997-05-29 2002-09-10 Btg International Limited Orally active iron (III) chelators
GB9723078D0 (en) * 1997-10-31 1998-01-07 Cerebrus Ltd Chemical compounds
JPH11147377A (ja) * 1997-11-18 1999-06-02 Teijin Ltd 感熱転写リボン用二軸配向ポリエステルフィルム
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
DE60037819T2 (de) * 1999-08-27 2009-01-08 Invitrogen Corp., Carlsbad Metallbindende verbindungen und deren verwendung in zusammensetzungen für zellkulturmedien
US6846915B2 (en) 2001-08-13 2005-01-25 The Regents Of The University Of California Hydroxypyridonate and hydroxypyrimidinone chelating agents
US6426418B1 (en) 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
WO2003065991A2 (en) * 2002-02-05 2003-08-14 Bristol-Myers Squibb Company N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
NZ529657A (en) * 2003-11-20 2004-07-30 Apotex Inc Iron chelating cycloalkyl derivatives of 3-hydroxy-4-pyridinones
CA2488034C (en) * 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
GB0506677D0 (en) * 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
KR101695807B1 (ko) 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 화합물
CA2733931A1 (en) * 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
ES2964383T3 (es) * 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
MX2011006241A (es) 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
CN101906069B (zh) * 2009-06-02 2012-12-12 首都医科大学 (s)-2-取代-(3'-乙酰基-2'-吡啶酮-1'-基)乙酸及其制备方法和应用
CN102712591B (zh) * 2009-07-03 2014-06-25 阿普泰克斯科技公司 3-羟基吡啶-4-酮的氟化衍生物
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN103118973B (zh) * 2010-07-27 2016-03-23 科莱恩金融(Bvi)有限公司 羟基吡啶酮或其盐用于稳定化过氧化氢或释放过氧化氢的物质的用途
CN105017138A (zh) * 2015-08-06 2015-11-04 中国科学技术大学 一种乙二醇化3-羟基吡啶-4-酮类化合物及其制备方法和用途
CN110790737B (zh) * 2019-11-07 2022-07-22 河南中烟工业有限责任公司 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518098A1 (de) * 1963-09-19 1969-04-10 Pfizer & Co C Verfahren zur Herstellung von Pyromekonsaeurederivaten
GB2118176B (en) * 1982-03-24 1985-12-04 Nat Res Dev Pharmaceutical compositions
GB8308054D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
US4908371A (en) * 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
DE58906384D1 (de) * 1988-01-20 1994-01-27 Ciba Geigy Verfahren zur Herstellung von Komplexverbindungen.
EP0335745A1 (en) * 1988-03-31 1989-10-04 The Royal Free Hospital School Of Medicine Process for producing pyrid-4-ones
US4980371A (en) * 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
US5112968A (en) * 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
GB9100465D0 (en) * 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
GB9209078D0 (en) * 1992-04-27 1992-06-10 Hider Robert C Pharmaceutical compositions
CA2100623A1 (en) * 1992-07-17 1994-01-18 Michiyuki Sendai Cephem compounds, their production and use
GB9216506D0 (en) * 1992-08-04 1992-09-16 Rice Evans Catherine A Improvements in or relating to the treatment of sickle cell disease
GB9217099D0 (en) * 1992-08-12 1992-09-23 British Tech Group Pharmaceutical compositions
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation

Also Published As

Publication number Publication date
AU6584596A (en) 1997-04-10
TR199600765A2 (tr) 1997-05-21
US5688815A (en) 1997-11-18
AR005419A1 (es) 1999-06-23
BR9603929A (pt) 1998-06-09
IL119316A (en) 2000-08-13
ES2244967T3 (es) 2005-12-16
HU9602681D0 (en) 1996-11-28
EP0768302A2 (de) 1997-04-16
EP0768302B1 (de) 2005-07-06
ATE299135T1 (de) 2005-07-15
EP0768302A3 (de) 1998-02-25
NZ299452A (en) 1998-06-26
DE59611243D1 (de) 2005-08-11
CA2186716A1 (en) 1997-03-30
IL119316A0 (en) 1996-12-05
ZA968150B (en) 1997-04-01
HUP9602681A1 (en) 1997-09-29
SA96170399B1 (ar) 2007-01-20
JPH09124603A (ja) 1997-05-13
KR970015576A (ko) 1997-04-28
CN1151399A (zh) 1997-06-11
NO964095L (no) 1997-04-01
NO964095D0 (no) 1996-09-27
PT768302E (pt) 2005-11-30
CZ284896A3 (en) 1997-04-16

Similar Documents

Publication Publication Date Title
MX9604367A (es) Hidroxipiridinonas novedosas.
MX9606744A (es) Acidos hidroxamicos sustituidos por sulfonamido arilico como inhibidores de metaloproteinasa de matriz.
BG103485A (en) Ketobanzamides as calpain inhibitors
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
BG101110A (en) Substituted pyrimidine compounds and their application
BG101112A (en) The use of heterocyclic compounds
TW289757B (es)
BG105784A (en) Triazole compounds with dopamine-d3-receptor affinity
ZA200109995B (en) Nematicidal Trifluorobutenes.
MY138966A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
BG105270A (en) Tetrahydropyridoethers
MX9709240A (es) Fenilpiridazinonas.
GB9308957D0 (en) Novel produgs
IN2012DE00109A (es)
PL285248A1 (en) Method of obtaining novel aminophenol derivatives
MY107819A (en) Preparation of substituted piperidines.
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
MY117934A (en) Process for the preparation of n-methyl-3-(1-methyl-4- piperidinyl)-1h-indole-5-ethanesulphonamide
GB2324091A (en) Metalloproteinase inhibitors
BG106002A (en) Process for preparing pesticidal intermediates
IN187760B (es)
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
ZA200005110B (en) Process for preparing intermediates.
GB9920959D0 (en) Novel process